Allergy Therapeutics plc

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.